You have 9 free searches left this month | for more free features.

Myelodysplastic Syndromes

Showing 26 - 50 of 3,174

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Interplay Between Immune and Metabolic Programs in

Recruiting
  • Myelodysplastic Syndromes
    • Toulouse, France
      IUCT-Oncopole University Hospital
    May 17, 2022

    Relapsed / Refractory MDS Trial (NCR300)

    Not yet recruiting
    • Relapsed / Refractory Myelodysplastic Syndromes
    • (no location specified)
    May 7, 2022

    Clonal Cytopenia of Undetermined Significance, MDS Trial in Saint Louis (Atorvastatin, Rosuvastatin)

    Not yet recruiting
    • Clonal Cytopenia of Undetermined Significance
    • Myelodysplastic Syndromes
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 28, 2022

    MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Feb 16, 2023

    MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)

    Terminated
    • MDS
    • Myelodysplastic Syndromes
    • APR-548 + Azacitidine
    • Tampa, Florida
    • +3 more
    Jul 20, 2022

    MDS Trial in Beijing (Lenalidomide, Azacitidine)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Beijing, China
      Peking union medical college hospital
    Aug 16, 2023

    Acute Myeloid Leukemia, MDS Trial in Rochester (Inpatient serious illness care program)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Inpatient serious illness care program
    • Rochester, New York
      University of Rochester
    Jun 21, 2022

    Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

    Not yet recruiting
    • Untreated Myelodysplastic Syndrome
    • Onureg + Venetoclax
    • Angers, France
    • +9 more
    Mar 13, 2023

    MDS Trial (AG-946, Placebo)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • (no location specified)
    Aug 4, 2022

    MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)

    Recruiting
    • Myelodysplastic Syndromes
    • Chronic Myelomonocytic Leukemia
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital, Chinese Acade
    Jul 30, 2023

    Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

    Recruiting
    • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
    • Ocala, Florida
    • +3 more
    Jan 30, 2023

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

    Recruiting
    • Chronic Myelomonocytic Leukemia
    • +5 more
    • Canakinumab
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 7, 2022

    Based on Quantitative Pharmacology in Patients With Lenalidomide

    Recruiting
    • Multiple Myeloma
    • +2 more
      • Jinan, Shandong, China
        the First Affiliated Hospital of Shandong First Medical Universi
      Oct 3, 2023

      Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • Myelodysplastic Syndromes
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, College of Medicine, Zhejiang Uni
      Sep 18, 2023

      Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)

      Recruiting
      • Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
      • TQB2618 injection azacitidine, AZA decitabine, DAC
      • ChengDu, Sichuan, China
        West China Hospital of Sichuan University
      Jun 16, 2022

      MDS Trial (Roxadustat in combination with retinoic acid)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Roxadustat in combination with retinoic acid
      • (no location specified)
      Aug 26, 2023

      MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Acute Myeloid Leukemia
      • (no location specified)
      Sep 2, 2022

      MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

      Recruiting
      • Myelodysplastic Syndromes
      • Myeloproliferative Chronic Myelomonocytic Leukemia
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 31, 2022

      Mean Platelet Volume and Its Relation to Risk Stratification of

      Completed
      • Myelodysplastic Syndromes
        • (no location specified)
        Jan 21, 2022

        MDS Trial in Beijing (Roxadustat, Luspatercept)

        Not yet recruiting
        • Myelodysplastic Syndromes
        • Beijing, China
          Peking union medical college hospital
        Aug 17, 2023

        MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

        Recruiting
        • Myelodysplastic Syndromes, de Novo
        • +10 more
        • Boston, Massachusetts
          Dana-Farber Cancer Institute
        Jan 23, 2023

        Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy

        Recruiting
        • Myelodysplastic Syndromes
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jan 31, 2023

          MDS Trial in Saint Louis (vosaroxin, Azacitidine)

          Active, not recruiting
          • Myelodysplastic Syndromes
          • Saint Louis, Missouri
            Washington University School of Medicine
          Mar 23, 2022

          MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

          Completed
          • MDS
          • +2 more
          • Placebo
          • Romiplostim
          • (no location specified)
          Nov 4, 2022

          Iron Deficiency Anemia Trial in Australia, Israel, Romania (KER-047)

          Recruiting
          • Iron Deficiency Anemia
          • Adelaide, South Australia, Australia
          • +8 more
          Jun 23, 2023